In a study of DNA-launched BTEs against EGFRvIII and HER2, which are expressed in 30% and 60% of GBMs, respectively, the combination of EGFRvIII-DBTE and HER2-DBTE resulted in 80% survival in a heterogenous GBM mouse model, vs. 20% and 10% for the EGFRvIII and HER2 treatment groups [44]. This evidence concerns the gene ERBB2 and glioblastoma.